- Home
- ZNTL vs FINS Comparison
ZNTL vs FINS Comparison
Compare ZNTL & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | FINS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 436.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZNTL | FINS |
|---|---|---|
| Price | $2.92 | $13.24 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $5.87 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 78.0K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.97% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $26,865,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $11.61 |
| 52 Week High | $3.19 | $12.57 |
Technical Indicators
Market Signals| Indicator | ZNTL | FINS |
|---|---|---|
| Relative Strength Index (RSI) | 91.10 | 55.29 |
| Support Level | $1.31 | $13.15 |
| Resistance Level | $1.46 | $13.30 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 90.29 | 79.49 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.